Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) represented a move of 0.68 percent or $-0.56 per share and closed its previous day trading session at $81.16. 775613 Shares were traded in the last trading session with an Average Volume of 880.69 Million Shares. The stock currently has a Market Capitalization of 8.14 Billion.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
The stock traded between $ 63.57 and $153.99 over 1-Year time period showing its price to sales ratio of 88.72. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $0.92 and 200-Day Simple Moving Average of $-18.76. Its Price to Free Cash Flow is 0 and Price to Book of 5.53.
Analyst’s recommended the stock as 2.1 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported its Actual EPS of $-2.43/share. The analysts offering Earnings Estimates for the company were believing that Alnylam Pharmaceuticals, Inc. could bring EPS of $-2.02/share. The difference between Actual EPS and Estimated EPS was -0.41 Percent. Thus showing an Earnings Surprise of -20.3 Percent.
Qorvo, Inc. (NASDAQ:QRVO)
In the last trading session, Qorvo, Inc. (NASDAQ:QRVO) added its value by 0.8% closing at the price of $65.81. The stock currently has market capitalization of 8.27 Billion, with average volume of 1.4 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Qorvo, Inc. (NASDAQ:QRVO) is showing beta of 0.98. This particular value of beta suggests that Qorvo, Inc. (NASDAQ:QRVO) has historically moved 98% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Qorvo, Inc. (NASDAQ:QRVO) is at $0.14.
The stock currently has RSI of 45.66. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Qorvo, Inc. is a provider of technologies and RF solutions for mobile, infrastructure and aerospace/defence applications. The Company operates through two subsidiaries: RF Micro Devices, Inc. (RFMD) and TriQuint Semiconductor, Inc. (TriQuint). RFMD designs and manufactures radio frequency solutions. TriQuint designs, develops and manufactures active and passive technologies, including power amplifier, switch and filter modules for the mobile device, network infrastructure, and defence and aerospace markets. Its products are used for wireless communications applications such as cellular and PCS, cordless telephony, wireless LANs, industrial radios, wireless security and remote meter reading. Qorvo, Inc.is based in United States.
Qorvo, Inc. (NASDAQ:QRVO) topped its 52-week high price of $86.84 on 03/12/18 and 52-Week Low Price of $61.00 on 11/13/18. The Stock currently has P/E (price to earnings ttm) of 487.48 and Weekly volatility of 2.62% and monthly volatility of 3.99% respectively.